The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation
Study Details
Study Description
Brief Summary
This study sought to determine the safety of the varicella vaccine pre- and post-transplantation when given to pediatric patients listed for solid organ transplantation. The study assessed the antibody response to a two-dose vaccine regimen and determined the durability of that antibody response at several intervals in the post-transplant period. As a secondary objective, the relationship between antibody titers and different variables were explored
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: varicella vaccine (VARIVAX) varicella vaccine (VARIVAX) |
Biological: varicella vaccine (VARIVAX)
|
Outcome Measures
Primary Outcome Measures
- Determination of the safety of VARIVAX™ [Up to 6 months]
Eligible subjects given a two-dose OMVV pre transplantation were monitored for Adverse Events. AE were monitored for up to six wk after each dose with the assistance of parent diaries.
- Determination of the safety of VARIVAX™ [up to 6 months]
All transplant recipients were monitored over the follow-up period for microbiological and clinical evidence of reactivation of other herpes group viruses.
- Determination of the proportion immunized who demonstrate seroconversion and maintain humoral immunity seroconversion at 6, 12 and 24 months post-transplantation [up to 12 months]
Control antigen was prepared in parallel from uninfected cells. A gpELISA antibody level of >0.6 gpEU/mL defined seroconversion, and a gpELISA antibody level exceeding 5 gpEU/mL defined seroprotection.
- Determination of the proportion immunized who demonstrate seroconversion and maintain humoral immunity seroconversion at 6, and 12 months post-transplantation [Up to 12 months]
VZV-specific antibodies were measured at Merck Research Laboratories using a previously validated ELISA method that detected antibodies to VZV glycoproteins purified from VZV-infected human fibroblasts.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Children > 9 months of age and adolescents < 18 years of age.
-
Pediatric transplant candidates who are in any of the following categories:
-
listed to receive kidney, liver, heart, lung or other or solid organ transplantation in a Canadian transplant centre
-
not yet officially listed, but are regarded by their physicians as transplant candidates by virtue of their underlying diseases
-
No clinical history for varicella.
-
Seronegative for antibodies to VZV except infants 9 - 12 months of age who may be seropositive due to maternal antibodies.
-
Informed consent obtained
Exclusion Criteria:
-
Previous immunization with varicella vaccine.
-
Any established immune deficiency (underlying disease or drug induced) or any neoplastic disease
-
Children on any oral and / or intravenous steroids within 3 months prior to immunization. Children on inhaled corticosteroids in excess of 800 mcg of beclomethasone dipropionate ( or equivalent ) per day.
-
Any exposure to varicella or herpes zoster in the previous 4 weeks involving household, playmate or hospital contacts.
-
Inability to delay the transplantation for up to 6 weeks following the last varicella immunization.
-
Presence of a person at increased risk for varicella infection in direct and unavoidable proximity with the vaccinees ( e.g. an immunocompromised sibling)
-
Past history of varicella or known positive antibody titer for varicella except infants 9 - 12 months of ages who may be seropositive due to maternal antibodies
-
Known hypersensitivity to any of the components of the vaccine, including neomycin and gelatin
-
Patients whose mothers are known to be seronegative and plan to become pregnant in the subsequent three months
-
Administration of VZIG or any other blood products in the previous six weeks (packed red blood cells excepted).
-
Any significant infection and/or fever at the time of vaccination
-
Any patient receiving or planning to receive salicylates in the six weeks after immunization
-
Any patient who has received any live vaccine for 6 weeks or killed vaccine for 2 weeks prior to or after the scheduled VARIVAX™ vaccination.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | The Hospital for Sick Children | Toronto | Ontario | Canada | M5G 1X8 |
Sponsors and Collaborators
- The Hospital for Sick Children
Investigators
- Principal Investigator: Upton Allen, MD, The Hospital for Sick Children, Toronto Canada
- Study Chair: Upton Allen, The Hospital for Sick Children
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 0019990029